For instance, Shaim et al. confirmed that utilizing genetically modified allogeneic NK cells with a suppressed αv integrin/transforming growth factor (TGF)-β axis or CRISPR-gene-edited TGF-receptor 2 (TGFBR2) dramatically increased the overall survival in mouse model by effectively targeting both GBM stem cells (GSCs) and non-GSCs [6, 59, 60]. The gene discussed is TGFB1; the disease is glioblastoma.